KOREA PHARMA Statistics

Total Valuation

KOREA PHARMA has a market cap or net worth of KRW 157.60 billion. The enterprise value is 142.81 billion.

Market Cap	157.60B
Enterprise Value	142.81B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 27, 2024

Share Statistics

KOREA PHARMA has 10.91 million shares outstanding. The number of shares has increased by 4.06% in one year.

Current Share Class	n/a
Shares Outstanding	10.91M
Shares Change (YoY)	+4.06%
Shares Change (QoQ)	-0.40%
Owned by Insiders (%)	64.60%
Owned by Institutions (%)	0.05%
Float	3.86M

Valuation Ratios

The trailing PE ratio is 41.52.

PE Ratio	41.52
Forward PE	n/a
PS Ratio	1.94
PB Ratio	2.20
P/TBV Ratio	2.34
P/FCF Ratio	32.86
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.57, with an EV/FCF ratio of 29.77.

EV / Earnings	37.66
EV / Sales	1.76
EV / EBITDA	13.57
EV / EBIT	18.47
EV / FCF	29.77

Financial Position

The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.32.

Current Ratio	3.81
Quick Ratio	2.76
Debt / Equity	0.32
Debt / EBITDA	2.58
Debt / FCF	4.77
Interest Coverage	2.11

Financial Efficiency

Return on equity (ROE) is 5.42% and return on invested capital (ROIC) is 3.85%.

Return on Equity (ROE)	5.42%
Return on Assets (ROA)	3.26%
Return on Invested Capital (ROIC)	3.85%
Return on Capital Employed (ROCE)	6.54%
Revenue Per Employee	606.55M
Profits Per Employee	28.30M
Employee Count	134
Asset Turnover	0.70
Inventory Turnover	2.46

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.01% in the last 52 weeks. The beta is 1.19, so KOREA PHARMA's price volatility has been higher than the market average.

Beta (5Y)	1.19
52-Week Price Change	-34.01%
50-Day Moving Average	15,717.40
200-Day Moving Average	16,961.00
Relative Strength Index (RSI)	31.51
Average Volume (20 Days)	20,952

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KOREA PHARMA had revenue of KRW 81.28 billion and earned 3.79 billion in profits. Earnings per share was 348.00.

Revenue	81.28B
Gross Profit	35.15B
Operating Income	6.09B
Pretax Income	3.91B
Net Income	3.79B
EBITDA	8.88B
EBIT	6.09B
Earnings Per Share (EPS)	348.00

Full Income Statement

Balance Sheet

The company has 37.69 billion in cash and 22.90 billion in debt, giving a net cash position of 14.79 billion or 1,356.35 per share.

Cash & Cash Equivalents	37.69B
Total Debt	22.90B
Net Cash	14.79B
Net Cash Per Share	1,356.35
Equity (Book Value)	71.44B
Book Value Per Share	6,576.49
Working Capital	54.31B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.05 billion and capital expenditures -3.25 billion, giving a free cash flow of 4.80 billion.

Operating Cash Flow	8.05B
Capital Expenditures	-3.25B
Free Cash Flow	4.80B
FCF Per Share	439.80

Full Cash Flow Statement

Margins

Gross margin is 43.25%, with operating and profit margins of 7.49% and 4.67%.

Gross Margin	43.25%
Operating Margin	7.49%
Pretax Margin	4.81%
Profit Margin	4.67%
EBITDA Margin	10.93%
EBIT Margin	7.49%
FCF Margin	5.90%

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.34%.

Dividend Per Share	50.00
Dividend Yield	0.34%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	14.38%
Buyback Yield	-4.06%
Shareholder Yield	-3.73%
Earnings Yield	2.41%
FCF Yield	3.04%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KOREA PHARMA has an Altman Z-Score of 4.78.

Altman Z-Score	4.78
Piotroski F-Score	n/a